Genmab — August 2016
-
så hvis vi tager ja-hatten på, så neutraliserers stigningen på 3% fra i går og US biotech er nede med 1,5% og usddkk - 0,5%.
-
Jeg har fået mail med svar fra Jan på
Bulders spørgsmål: "There was a question on the conference call for Genmab’s 1H results regarding a change in status on ct.gov to the ongoing subcut study. We have checked with Janssen and they tell us this is not the case, it is apparently an error and will be corrected". -
Gode tanker Dingle.
-
spændende
-
fremragende artikel - tak for den Sukkeralf. Det ser ud til, at vores bønner om fart på klinikken bliver hørt
-
Interessant i øvrigt, at du i det store hele fik Jan til at aflyse ofa i cancer...
-
var det ikke Novartis?
-
nårh ja - han taler om dem begge
-
...men Gilead er vel stadig kun research.
-
jeg føler mig stadig ikke helt overbevist om, at GENs duo kan noget som andres ikke kan
-
måske JJ kan vise os vejen med data fra deres programmer
-
Jo, der er ikke meget, der peger fremad der
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind